Skip to main content

Drug Interactions between metyrapone and Vagifem

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

metyraPONE estradiol topical

Applies to: metyrapone and Vagifem (estradiol topical)

MONITOR: Estrogen therapy may reduce the response to metyrapone test. The mechanism is related to an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in decreased cortisol clearance. The increase in circulating cortisol may directly interfere with test results, since the pharmacologic effect of metyrapone is to inhibit adrenal production of cortisol and corticosterone in order to elicit an increase in ACTH production by the pituitary.

MANAGEMENT: Clinicians should recognize the potential for a diminished response to metyrapone test in patients treated with estrogens.

References

  1. "Product Information. femhrt (ethinyl estradiol-norethindrone)." Parke-Davis
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Cerner Multum, Inc. (2015) "Canadian Product Information."
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer